Excellent response, NED in final follow-up, tumor size ≤10 mm (vs. >10 mm and ≤20 mm), and classic cancer subtype (vs. other aggressive subtypes) were ~1.4-fold, ~1.2-fold, ~1.4-fold, and ~1.1-fold higher, respectively, in patients with low CHK2 expression than in those with high CHK2 expression. This evidence concerns the gene CHEK2 and neoplasm.